Skip to main content

Table 1 Demographics and clinical characteristics of the study cohort (N = 107)

From: Treatment outcomes of cetuximab-containing regimen in locoregional recurrent and distant metastatic head and neck squamous cell carcinoma

 

Total

Locoregional recurrence

Distant metastasis

p-value

(n = 107)

(n = 66)

(n = 41)

Age, years (IQR)

60.2 (58.5–62.1)

60.5 (58.2–62.9)

59.9 (57.0–62.7)

0.710

Sex

   

0.289

 Male

100 (93.5%)

63 (95.5%)

37 (90.2%)

 

 Female

7 (6.5%)

3 (5.0%)

4 (9.8%)

 

Smoking

   

0.712

 Former or current

65 (60.7%)

41 (62.1%)

24 (58.5%)

 

 Never

42 (39.3%)

25 (37.9%)

17 (41.5%)

 

Betel nuts

   

0.264

 Former or current

89 (83.2%)

57 (86.4%)

32 (78.0%)

 

 Never

18 (16.8%)

9 (13.6%)

9 (22.0%)

 

Performance status

   

0.110

 ECOG = 0

71 (66.3%)

40 (60.6%)

31 (75.6%)

 

 ECOG≧1

36 (33.6%)

26 (39.4%)

10 (24.4%)

 

Primary tumor location

   

0.043¢

 Oral cavity

54 (50.5%)

40 (60.6%)

14 (34.1%)

 

 Oropharynx

19 (17.8%)

7 (10.6%)

12 (29.3%)

 

 Hypopharynx

22 (20.6%)

11 (16.7%)

11 (26.8%)

 

 Larynx

9 (8.4%)

6 (9.1%)

3 (7.3%)

 

 Other sites†

3 (2.8%)

2 (3.0%)

1 (2.4%)

 

Differentiation of tumor

   

0.248

 Well to moderate

68 (63.5%)

38 (57.6%)

30 (73.2%)

 

 Poor

9 (8.4%)

6 (9.1%)

3 (7.3%)

 

 Not available

30 (28.0%)

22 (33.3%)

8 (19.5%)

 

Previous systemic treatments

   

0.086

 Neoadjuvant chemotherapy

40 (37.4%)

27 (31.8%)

13 (25.0%)

 

 Primary CCRT

47 (43.9%)

33 (38.8%)

14 (26.9%)

 

 Adjuvant CCRT

50 (46.7%)

25 (29.4%)

25 (48.1%)

 

Treatment after recurrence

   

0.663

 EXTREME regimenγ

68 (63.6%)

43 (65.2%)

25 (61.0%)

 

 Salvage surgery

14 (21.2%)

14 (21.2%)

–

 

 Reirradiation

15 (22.7%)

15 (22.7%)

–

 

Recurrence after RT

   

0.035

  <  6 months

50 (46.7%)

37 (56.1%)

13 (31.7%)

 

 ≧ 6 months

49 (45.8%)

26 (39.4%)

23 (56.1%)

 

 Not available

8 (7.5%)

3 (4.5%)

5 (12.2%)

 
  1. Abbreviations: IQR interquartile range, R/M SCCHN recurrent or metastatic squamous cell carcinoma of the head and neck, CCRT concurrent chemoradiotherapy
  2. Data are presented with median (IQR) or n (%). Bold indicates statistically significant at p < 0.05
  3. †External auditory canal in one patients and neck lymph node in two patients
  4. ¶ Patient may have received systemic treatment in more than one context
  5. ¢ Fisher’s exact test
  6. γFor those who did not receive EXTREME regimen, the combination of cetuximab-containing regimen included: MEMOCLUB (n = 28, a frequently used regimen in platinum-refractory HNSCC adapted to local practice [15], methotrexate (n = 3), cetuximab alone (n = 5), pembrolizumab (n = 1), pembrolizumab + paclitaxel (n = 1), and TPF (n = 1)